Management of diabetic kidney disease: where do we stand?: A narrative review

被引：12
作者：
Sindhu, Devada [1 ]
Sharma, Gaurav Shekhar [1 ,3 ]
Kumbala, Damodar [2 ]
机构：
[1] AIIMS Rishikesh, Dept Nephrol, Dehra Dun, India
[2] Renal Associates Baton Rogue, Baton Rogue, LA USA
[3] AIIMS Rishikesh, Dept Nephrol, Dehra Dun 249203, India
来源：
MEDICINE | 2023年 / 102卷 / 13期
关键词：
diabetes mellitus; diabetic kidney disease; diabetic nephropathy; CARDIOVASCULAR OUTCOMES; TYPE-2; MICROALBUMINURIA; NEPHROPATHY; PROGRESSION; PREVENTION; DIALYSIS; THERAPY; UPDATE;
D O I：
10.1097/MD.0000000000033366
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Diabetic kidney disease is the leading cause of chronic kidney disease and end-stage renal disease. The pathogenesis and risk factors for the development of diabetic kidney disease are complex and multifaceted, resulting in glomerular hypertrophy, tubulointerstitial inflammation, and fibrosis. The clinical staging progresses over 5 stages from early hyperfiltration to overt nephropathy. Primary prevention like glycaemic control, control of blood pressure, treatment of dyslipidemia and lifestyle modifications have shown promising benefits. Despite widespread research, very few drugs are available to retard disease progression. More literature and research are needed to fill these lacunae. We carried out a literature search focusing on newer updates in diabetic kidney disease pathophysiology, diagnosis and management using a PubMed search through the National library of medicine using keywords "Diabetic kidney disease," and "Diabetic nephropathy" till the year 2022. We have summarized the relevant information from those articles.
引用
收藏
页数：7
相关论文
共 49 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]   ICE guidance on sotagliflozin for type 1 diabetes [J].
Adler, Amanda I. ;
Cronshaw, Jessica ;
Prescott, Carl ;
Patel, Sanjeev ;
Donegan, Eleanor ;
Hayre, Jasdeep .
LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (04) :274-275
[3]   Diabetic Kidney Disease Challenges, Progress, and Possibilities [J].
Alicic, Radica Z. ;
Rooney, Michele T. ;
Tuttle, Katherine R. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (12) :2032-2045
[4]   4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S46-S59
[5]  
Amer Diabet Assoc Professional Pra, 2022, DIABETES CARE, V45, pS175, DOI [10.2337/dc22-S011, 10.2337/dc22-ad08a]
[6]   Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) [J].
Ansquer, JC ;
Foucher, C ;
Rattier, S ;
Taskinen, MR ;
Steiner, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) :485-493
[7]   Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes [J].
Bakris, George L. ;
Agarwal, Rajiv ;
Anker, Stefan D. ;
Pitt, Bertram ;
Ruilope, Luis M. ;
Rossing, Peter ;
Kolkhof, Peter ;
Nowack, Christina ;
Schloemer, Patrick ;
Joseph, Amer ;
Filippatos, Gerasimos .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2219-2229
[8]   Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus [J].
Bell, Christopher G. ;
Teschendorff, Andrew E. ;
Rakyan, Vardhman K. ;
Maxwell, Alexander P. ;
Beck, Stephan ;
Savage, David A. .
BMC MEDICAL GENOMICS, 2010, 3
[9]   Role of the renin angiotensin system in diabetic nephropathy [J].
Chawla, Tanuj ;
Sharma, Deepika ;
Singh, Archana .
WORLD JOURNAL OF DIABETES, 2010, 1 (05) :141-145
[10]  
Cooper BA, 2004, PERITON DIALYSIS INT, V24, P176
12345